Biodexa Pharmaceuticals PLC
("Biodexa" or the "Company")
Biodexa Enters Into Exclusive License to eRapa, a Phase 3 Ready Asset for the
Treatment of Familial Adenomatous Polyposis (FAP)
Worldwide rights come with $17 million in non-dilutive grant funding for Pivotal Phase 3 trial in FAP
An estimated 100,000 in U.S. and Europe are afflicted with FAP, precancerous polyps that typically lead to surgical removal of the colon and/or rectum
In FAP, eRapa holds the potential of delaying or preventing surgical intervention
Multiple opportunities seen in other indications, including bladder and prostate cancers
- FAP is a substantially genetic orphan disease for which there...
Login or create a forever free account to read this news
Sign up/Log in